Wegovy, a popular semaglutide injection, is administered weekly using a user-friendly pen device
From a clinical perspective, consistent monitoring supports shared decision-making
People with poorly controlled diabetes face a higher risk of recurrent yeast infections due to high blood sugar, weakened immunity, and favorable conditions for Candida
Earlier use of GLP-1 receptor agonists with proven cardiovascular benefits in patients with established cardiovascular disease or high cardiovascular risk has been recommended in guidelines published by the European Association for the Study of Diabetes (EASD), with oral semaglutide associated with cardiovascular safety in PIONEER 6 and cardiovascular benefits being evaluated in the ongoing SOUL study [1, 12, 15]
Following the medication guide and consistency with Mounjaro supports stable blood levels and minimizes the risk of missed doses
Milestones of GLP-1 mechanistic research and drug development